Germany’s Merck KGaA has presented detailed results from cohort B of the global Phase II WILLOW study of enpatoran, an ...

Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary ...

Hoping to gain an edge in the rapidly growing market are MilliporeSigma and Simtra BioPharma Solutions, which have forged a ...

Merck KGaA (Merck)’s investigational lupus therapy enpatoran will be advancing to Phase III trials after meeting the primary endpoint in one cohort but missing it in another. While the drug met the ...

Merck KGaA’s antibody-drug conjugate (ADC), precemtabart tocentecan, has shown to be safe and tolerable in a Phase Ib trial.

DWS Group GmbH KGaA's significant public companies ownership suggests that the key decisions are influenced by shareholders from the larger public Deutsche Bank Aktiengesellschaft owns 79% of the ...

The ISG State of the Agentic AI Market report findings will be presented at the ISG AI Impact Summit, June 23–24 at the ...

Merck KGaA is filing for global regulatory approvals of pimicotinib after it met primary and secondary endpoints in a Phase III TGCT trial.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Two months after saying it was in advanced talks to acquire SpringWorks Therapeutics, Merck KGaA, Darmstadt, Germany, has announced it agreed to purchase the developer of drugs for severe rare ...

Germany’s Merck MRK-0.64%decrease; red down pointing triangle KGaA shares dropped after the company slashed its full-year outlook on the back of uncertainty around tariffs and foreign-exchange ...

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US at a time when many companies are seeking to increase investment in ...